Novartis to acquire The Medicines Co. for $9.7bn
Novartis AG agreed to acquire atherosclerotic cardiovascular disease (ASCVD)-focused public US biotech The Medicines Co. (TMC) in an all-cash transaction with a fully diluted equity value of $9.7bn. Approved by both boards, the deal is expected to close in Q1 2020.
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com